INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 299 filers reported holding INTELLIA THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 1.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,086,696 | -21.9% | 413,874 | +0.8% | 0.00% | -50.0% |
| Q2 2023 | $16,748,020 | -66.5% | 410,692 | -69.4% | 0.00% | -60.0% |
| Q1 2023 | $49,982,536 | +108.3% | 1,341,093 | +95.0% | 0.01% | +66.7% |
| Q4 2022 | $23,996,818 | +42.5% | 687,785 | +128.6% | 0.00% | +50.0% |
| Q3 2022 | $16,836,000 | -19.4% | 300,871 | -25.5% | 0.00% | 0.0% |
| Q2 2022 | $20,891,000 | -14.7% | 403,635 | +19.7% | 0.00% | 0.0% |
| Q1 2022 | $24,496,000 | -28.7% | 337,083 | +16.0% | 0.00% | -33.3% |
| Q4 2021 | $34,349,000 | -14.5% | 290,495 | -3.0% | 0.00% | -25.0% |
| Q3 2021 | $40,162,000 | -12.1% | 299,368 | +6.1% | 0.00% | -20.0% |
| Q2 2021 | $45,700,000 | +67.4% | 282,260 | -17.0% | 0.01% | +66.7% |
| Q1 2021 | $27,305,000 | +345.8% | 340,234 | +202.2% | 0.00% | +200.0% |
| Q4 2020 | $6,125,000 | +423.1% | 112,577 | +91.1% | 0.00% | – |
| Q3 2020 | $1,171,000 | +123.0% | 58,901 | +135.8% | 0.00% | – |
| Q2 2020 | $525,000 | +20.1% | 24,976 | -30.1% | 0.00% | – |
| Q1 2020 | $437,000 | 0.0% | 35,750 | +19.8% | 0.00% | – |
| Q4 2019 | $437,000 | +7.4% | 29,838 | -2.0% | 0.00% | – |
| Q3 2019 | $407,000 | -64.0% | 30,432 | -55.9% | 0.00% | – |
| Q2 2019 | $1,132,000 | -35.6% | 69,085 | -32.9% | 0.00% | – |
| Q1 2019 | $1,758,000 | +427.9% | 102,951 | +322.8% | 0.00% | – |
| Q4 2018 | $333,000 | -69.2% | 24,352 | -35.4% | 0.00% | – |
| Q3 2018 | $1,080,000 | -68.7% | 37,716 | -70.1% | 0.00% | -100.0% |
| Q2 2018 | $3,449,000 | +1446.6% | 126,075 | +1093.7% | 0.00% | – |
| Q1 2018 | $223,000 | +28.9% | 10,562 | +17.4% | 0.00% | – |
| Q4 2017 | $173,000 | -73.7% | 8,995 | -66.0% | 0.00% | – |
| Q3 2017 | $657,000 | +62.2% | 26,418 | +4.4% | 0.00% | – |
| Q2 2017 | $405,000 | +61.4% | 25,305 | +41.8% | 0.00% | – |
| Q1 2017 | $251,000 | +483.7% | 17,840 | +443.6% | 0.00% | – |
| Q4 2016 | $43,000 | +290.9% | 3,282 | +404.9% | 0.00% | – |
| Q3 2016 | $11,000 | +266.7% | 650 | +392.4% | 0.00% | – |
| Q2 2016 | $3,000 | – | 132 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |